Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 6/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.48 |
| ▸ | WNT1 | P04628 | 4/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 7/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.43 |
| ▸ | PARP1 | P09874 | 6/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL440170 | 0.98 | MEN1 (0.54) | MEN1CYP2D6KMT2AGSK3BDYRK1A | |
| SCHEMBL17252020 | 0.82 | MEN1 (0.47) | MEN1CYP2D6KMT2ADYRK1AHRH3 | |
| SCHEMBL18624033 | 0.82 | ACHE (0.50) | MEN1CYP2D6KMT2AGSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL461873 | 0.81 | MEN1 (0.49) | MEN1CYP2D6KMT2ADYRK1AHRH3 | |
| Hydrochloric Acid SCHEMBL17243327 | 0.81 | ACHE (0.49) | MEN1CYP2D6KMT2AGSK3BDYRK1A | |
| SCHEMBL16462782 | 0.81 | WNT1 (0.47) | GSK3BDYRK1AWNT1TNKSTNKS2 | |
| SCHEMBL463382 | 0.79 | TNKS (0.43) | TNKSTNKS2PARP1 | |
| SCHEMBL438489 | 0.78 | TNKS (0.48) | MEN1KMT2ATNKSTNKS2PARP1 | |
| SCHEMBL15219421 | 0.77 | KDM5A (0.51) | GSK3BDYRK1A | |
| SCHEMBL9980816 | 0.74 | MEN1 (0.55) | MEN1CYP2D6KMT2AGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570116-B2 | 1,4-dicarbonyl-piperidyl derivatives | MERCK PATENT GMBH (DE) | 2020-02-25 | — | — | US | disclosed |
| US-20190092751-A1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-03-28 | — | — | US | disclosed |
| US-9901577-B2 | Oxoquinazolinyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9901577-B2 | Oxoquinazolinyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9809598-B2 | Heterocyclyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-9809598-B2 | Heterocyclyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| WO-2017076484-A1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-05-11 | — | — | WO | disclosed |
| EP-3027598-B1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20160184310-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-06-30 | — | — | US | disclosed |
| US-20160184310-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-06-30 | — | — | US | disclosed |
| WO-2015169421-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015014442-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570116-B2 | 1,4-dicarbonyl-piperidyl derivatives | TNKS, TANK, TBKBP1 | MEN1 3993/4885CYP2D6 2103/4885KMT2A 530/4885 |
| US-20190092751-A1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | TNKS, TANK, TBKBP1 | MEN1 3993/4885CYP2D6 2103/4885KMT2A 530/4885 |
| US-20160184310-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | TANK, IRAK3, TNKS | MEN1 3932/4885CYP2D6 2112/4885KMT2A 1097/4885 |
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | MEN1 4411/4885CYP2D6 1264/4885KMT2A 667/4885 |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | TNKS, TANK, TBKBP1 | MEN1 4039/4885CYP2D6 1952/4885KMT2A 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.